COMP <GO>
IONS vs ABBV // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Ionis Pharmaceuticals Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: IONS 4
— ABBV 10
▲ OPTIONS IMPLIED MOVE & PUT/CALL SKEW LEADER: IONS
LAST: $43.52 (-1.96%) • MKT CAP: $7.38B
options-implied-move
7.20%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
options-implied-move
7.40%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IONS VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IONS | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 70.20% | +25.80 | IONS | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -20.90% | 29.00% | -49.90 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -4.34% | 3.47% | -7.81 | ABBV | /fcf-yield <GO> |
| Operating Margin | -40.40% | 24.60% | -65.00 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -40.40% | 6.90% | -47.30 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 33.80% | 8.60% | +25.20 | IONS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.08 | 5.33 | -4.25 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | 7.20% | 7.40% | -0.20 | IONS | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.1 | 72.8 | -29.64 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.09 | 1.15 | -0.06 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.0x | 113.1x | -91.10 | IONS | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.38B | $513.86B | -$506.48B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IONS REV | ABBV REV | IONS GROSS % | ABBV GROSS % | IONS FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $943.7M | $61.16B | 98.3% | 70.2% | -$320.0M | $17.82B |
| FY 2024 | $705.1M | $56.33B | 98.4% | 70.0% | -$546.2M | $17.83B |
| FY 2023 | $787.6M | $54.32B | 44.0% | 44.0% | -$343.0M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IONS // BETA 1.09
ABBV // BETA 1.15